{"nctId":"NCT00999908","briefTitle":"Comparison of the Effects of Indacaterol and Tiotropium on Inspiratory Capacity","startDateStruct":{"date":"2009-10"},"conditions":["Chronic Obstructive Pulmonary Disease"],"count":54,"armGroups":[{"label":"Indacaterol 150 μg-tiotropium 18 μg-placebo","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 μg","Drug: Tiotropium 18 μg","Drug: Placebo"]},{"label":"Tiotropium 18 μg-placebo-indacaterol 150 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 μg","Drug: Tiotropium 18 μg","Drug: Placebo"]},{"label":"Placebo-indacaterol 150 μg-tiotropium 18 μg","type":"EXPERIMENTAL","interventionNames":["Drug: Indacaterol 150 μg","Drug: Tiotropium 18 μg","Drug: Placebo"]}],"interventions":[{"name":"Indacaterol 150 μg","otherNames":[]},{"name":"Tiotropium 18 μg","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Diagnosis of moderate (as classified by the Global Initiative for Chronic Obstructive Lung Disease \\[GOLD\\] Guidelines, 2007) chronic obstructive pulmonary disease (COPD) and:\n\n  1. Smoking history of at least 10 pack-years.\n  2. Forced expiratory volume in 1 second (FEV1) \\< 80% and ≥ 50% of the predicted normal value.\n  3. Post-bronchodilator FEV1/Force vital capacity (FVC) \\< 0.7.\n\nExclusion Criteria:\n\n* Patients who have had a COPD exacerbation requiring systemic glucocorticosteroid treatment or antibiotics and/or hospitalization in the 6 weeks prior to screening.\n* Patients who have had a respiratory tract infection within 6 weeks prior to screening.\n* Patients with concomitant pulmonary disease.\n* Patients with alpha-1-antitrypsin deficiency.\n* Patients with contraindications for tiotropium treatment.\n* Patients with a history of hypersensitivity to any of the study drugs or to drugs from similar drug classes.\n\nOther protocol-defined inclusion/exclusion criteria applied to the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"40 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Peak Inspiratory Capacity Assessed With Spirometry in the 4 Hours After Treatment","description":"During the 4 hours following inhalation of the study treatment, inspiratory capacity (IC) was measured with spirometry conducted according to internationally accepted standards. IC was measured 3 times each at 30, 60, 120, 180, and 240 minutes post-dose and the highest value was reported in liters.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.705","spread":"0.676"},{"groupId":"OG001","value":"2.630","spread":"0.601"},{"groupId":"OG002","value":"2.557","spread":"0.561"}]}]}]},{"type":"SECONDARY","title":"Forced Expiratory Volume in 1 Second (FEV1) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) in the 4 Hours After Treatment","description":"FEV1 was measured with spirometry conducted according to internationally accepted standards. Measurements were made 30, 60, 120, 180, and 240 minutes post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.744","spread":"0.419"},{"groupId":"OG001","value":"1.767","spread":"0.449"},{"groupId":"OG002","value":"1.642","spread":"0.409"}]}]}]},{"type":"SECONDARY","title":"Force Vital Capacity (FVC) Standardized (With Respect to Length of Time) Area Under the Curve (AUC) in the 4 Hours After Treatment","description":"FVC was measured with spirometry conducted according to internationally accepted standards. Measurements were made 30, 60, 120, 180, and 240 minutes post-dose. The standardized AUC FEV1 was calculated as the sum of trapezoids divided by the length of time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.140","spread":"0.700"},{"groupId":"OG001","value":"3.176","spread":"0.788"},{"groupId":"OG002","value":"3.048","spread":"0.753"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":54},"commonTop":[]}}}